HL-60 Cells

HL-60 cells, originating from a 36-year-old female with acute promyelocytic leukemia, serve as a vital model in cancer research, particularly in studying hematological malignancies, due to their ability to differentiate into mature white blood cells and mimic innate immune responses, aiding in the understanding of leukemic progression, cellular oncogene expression, and therapeutic target identification.
The ability of HL-60 cells to differentiate into mature white blood cells, such as granulocytes and monocytes, through agents like dimethyl sulfoxide (DMSO) or retinoic acid, underscores their significance in studies related to human myeloid cell differentiation and sheds light on the mechanisms underpinning leukemic progression and the efficacy of therapeutic interventions.
HL-60 human myeloid leukemia cells are integral to research focusing on apoptosis, cell activation, and the cell cycle, including the regulation of key oncogenes like the c-myc proto-oncogene and tumor necrosis factor (TNF-alpha). Their capability to form extracellular traps, structures involved in trapping and killing pathogens, which mirrors the innate immune response seen in primary neutrophils, makes HL-60 cells a useful model for studying the immune aspects of leukemia and how leukemic cells interact with the immune system.
Moreover, the responsiveness of HL-60 cells to signaling pathways such as the MAPK pathway and various kinases is crucial for dissecting the molecular mechanisms driving leukemic cell proliferation and differentiation. This aspect is particularly beneficial for identifying therapeutic targets and developing new treatment strategies for leukemia.
HL-60 cells are a critical resource in cancer research, offering insights into hematological malignancies, leukemic progression, and potential therapeutic targets through their unique differentiation capabilities and mimicry of immune responses.